Richard Wang, Ph. D and MBA, Chief Executive Officer, Fosun Kite Biotechnology Co. Ltd (a joint venture between Fosun Pharma and Kite Pharma), since March, 2017. Prior to joining Fosun Kite, Richard was a Chief Operation Officer for the Cellular Biomedicine Group (NASDAQ: CBMG). Richard led CBMG day-to-day operations and provided leadership and oversight to multiple functions (e.g., preclinical pharmacology, clinical development, manufacturing and technology (CMC), regulatory, quality assurance, project and administration), and was specifically responsible for the company’s stem cell technology platform and therapeutic business unit. He also supported the company’s immunotherapy pipeline (CAR-T and therapeutic vaccine) from the aspects of manufacturing, clinical development and registration strategy. Before that, Richard functioned as a site leader, senior director and head of operations for the GSK R&D Center in China, a director of strategic alliance, portfolio and operations for the AstraZeneca Innovation Center China, an associate director of discovery and early development project management in Bristol-Myers Squibb US, and a discovery group leader and senior scientist of the Procter & Gamble Pharmaceutical in the US, for more than 20 years with increasing leadership responsibilities in the therapeutic areas of oncology, neuroscience, muscular-skeletal and inflammatory diseases.